Pulmonary hypertension complicating interstitial lung disease and COPD

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 5, 2013, Pages 600-619

  Shino, Michaely ^a   Lynch, Josephp ^a   Saggar, Rajeev ^b   Abtin, Fereidoun ^c   Belperio, Johna ^a   Saggar, Rajan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; interstitial lung disease; pulmonary hypertension; sarcoidosis

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CORTICOSTEROID; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PRASTERONE; PROSTACYCLIN; PROSTAGLANDIN E2; RHO KINASE INHIBITOR; SILDENAFIL; SITAXSENTAN; TRANSFORMING GROWTH FACTOR BETA; TREPROSTINIL; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

AREA UNDER THE CURVE; ARTICLE; CAPILLARY WALL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENETIC SUSCEPTIBILITY; HEART CATHETERIZATION; HEART OUTPUT; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LANGERHANS CELL HISTIOCYTOSIS; LUNG BLOOD VESSEL; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; LYMPHANGIOLEIOMYOMATOSIS; MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY;

HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SARCOIDOSIS; SARCOIDOSIS, PULMONARY;

EID: 84884230491     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1356548     Document Type: Article

References (277)

1. Nadrous H. F., Pellikka P. A., Krowka M. J., et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest: 2005; 128 4 2393 2399
2. Fell C. D., Martinez F. J. The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. Chest: 2007; 131 3 641 643
3. Nunes H., Humbert M., Capron F., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax: 2006; 61 1 68 74
4. Badesch D. B., Tapson V. F., McGoon M. D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med: 2000; 132 6 425 434
5. Kuhn K. P., Byrne D. W., Arbogast P. G., Doyle T. P., Loyd J. E., Robbins I. M. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med: 2003; 167 4 580 586
6. Trad S., Amoura Z., Beigelman C., et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum: 2006; 54 1 184 191
7. Launay D., Sitbon O., Le Pavec J., et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford): 2010; 49 3 490 500
8. Fartoukh M., Humbert M., Capron F., et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med: 2000; 161 1 216 223
9. Le Pavec J., Lorillon G., Jaïs X., et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest: 2012; 142 5 1150 1157
10. Meraj R., Wikenheiser-Brokamp K. A., Young L. R., McCormack F. X. Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med: 2012; 33 5 486 497
11. Cottin V., Harari S., Humbert M., et al. Groupe d'Etudes et de Recherche sur les Maladies "Orphelineso" Pulmonaires (GERMo"Oo"P). Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J: 2012; 40 3 630 640
12. Lettieri C. J., Nathan S. D., Barnett S. D., Ahmad S., Shorr A. F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest: 2006; 129 3 746 752
13. Shorr A. F., Davies D. B., Nathan S. D. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest: 2002; 122 1 233 238
14. Strange C., Highland K. B. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med: 2005; 11 5 452 455
15. Chaouat A., Bugnet A. S., Kadaoui N., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2005; 172 2 189 194
16. Saggar R., Saggar R., Aboulhosn J., Belperio J. A., Zisman D. A., Lynch J. P. III. Diagnosis and hemodynamic assessment of pulmonary arterial hypertension. Semin Respir Crit Care Med: 2009; 30 4 399 410
17. Hoeper M. M., Lee S. H., Voswinckel R., et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol: 2006; 48 12 2546 2552
18. Arcasoy S. M., Christie J. D., Ferrari V. A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med: 2003; 167 5 735 740
19. Nathan S. D., Shlobin O. A., Barnett S. D., et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med: 2008; 102 9 1305 1310
20. Zisman D. A., Ross D. J., Belperio J. A., et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med: 2007; 101 10 2153 2159
21. Rich J. D., Shah S. J., Swamy R. S., Kamp A., Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest: 2011; 139 5 988 993
22. Adkins J. M., Collard H. R. Idiopathic pulmonary fibrosis. Semin Respir Crit Care Med: 2012; 33 5 433 439
23. Raghu G., Collard H. R., Egan J. J., et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med: 2011; 183 6 788 824
24. Lynch J. P. III, Saggar R., Weigt S. S., Zisman D. A., White E. S. Usual interstitial pneumonia. Semin Respir Crit Care Med: 2006; 27 6 634 651
25. Raghu G., Weycker D., Edelsberg J., Bradford W. Z., Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2006; 174 7 810 816
26. Gribbin J., Hubbard R. B., Le Jeune I., Smith C. J., West J., Tata L. J. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax: 2006; 61 11 980 985
27. Whelan T. P., Dunitz J. M., Kelly R. F., et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant: 2005; 24 9 1269 1274
28. Lynch J. P. III, Saggar R., Weigt S. S., Ross D. J., Belperio J. A. Overview of lung transplantation and criteria for selection of candidates. Semin Respir Crit Care Med: 2006; 27 5 441 469
29. Simonneau G., Galiè N., Rubin L. J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol: 2004; 43 (12, Suppl S): 5S 12S
30. Lederer D. J., Arcasoy S. M., Wilt J. S., D'Ovidio F., Sonett J. R., Kawut S. M. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2006; 174 6 659 664
31. Nathan S. D., Shlobin O. A., Ahmad S., Urbanek S., Barnett S. D. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest: 2007; 131 3 657 663
32. Patel N. M., Lederer D. J., Borczuk A. C., Kawut S. M. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest: 2007; 132 3 998 1006
33. Shorr A. F., Wainright J. L., Cors C. S., Lettieri C. J., Nathan S. D. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J: 2007; 30 4 715 721
34. Nathan S., Saggar R.. III JL. Lung transplantation for interstitial lung disorders. In: Lynch J. P. III, Ross D. J., eds. Lung and Heart-Lung Transplantation. New York, NY Taylor & Francis Group: 2006; 165 204
35. Colombat M., Mal H., Groussard O., et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: Histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol: 2007; 38 1 60 65
36. Cassan S. M., Divertie M. B., Brown A. L. Jr. Fine structural morphometry on biopsy specimens of human lung. 2. Diffuse idiopathic pulmonary fibrosis. Chest: 1974; 65 3 275 278
37. Leach R. M., Treacher D. F. Clinical aspects of hypoxic pulmonary vasoconstriction. Exp Physiol: 1995; 80 5 865 875
38. Wood J. G., Johnson J. S., Mattioli L. F., Gonzalez N. C. Systemic hypoxia increases leukocyte emigration and vascular permeability in conscious rats. J Appl Physiol: 2000; 89 4 1561 1568
39. Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax: 1963; 18 225 237
40. Keane M. P., Belperio J. A., Burdick M. D., Lynch J. P., Fishbein M. C., Strieter R. M. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2001; 164 12 2239 2242
41. Keane M. P., Arenberg D. A., Lynch J. P. III., et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol: 1997; 159 3 1437 1443
42. Renzoni E. A., Walsh D. A., Salmon M., et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med: 2003; 167 3 438 443
43. Wright L., Tuder R. M., Wang J., Cool C. D., Lepley R. A., Voelkel N. F. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med: 1998; 157 1 219 229
44. Charbeneau R. P., Peters-Golden M. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond): 2005; 108 6 479 491
45. Uguccioni M., Pulsatelli L., Grigolo B., et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol: 1995; 48 4 330 334
46. Giaid A., Michel R. P., Stewart D. J., Sheppard M., Corrin B., Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet: 1993; 341 8860 1550 1554
47. Hoeper M. M., Galiè N., Simonneau G., Rubin L. J. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med: 2002; 165 9 1209 1216
48. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med: 2004; 351 14 1425 1436
49. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med: 2007; 28 1 117 125, viii
50. Tuder R. M., Cool C. D., Geraci M. W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med: 1999; 159 6 1925 1932
51. Zisman D. A., Karlamangla A. S., Kawut S. M., et al. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest: 2008; 133 3 640 645
52. Ghanem M. K., Makhlouf H. A., Agmy G. R., Imam H. M., Fouad D. A. Evaluation of recently validated non- invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients. Ann Thorac Med: 2009; 4 4 187 196
53. Modrykamien A. M., Gudavalli R., McCarthy K., Parambil J. Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. Respir Care: 2010; 55 5 584 588
54. Swigris J. J., Olson A. L., Shlobin O. A., Ahmad S., Brown K. K., Nathan S. D. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology: 2011; 16 3 439 445
55. Boutou A. K., Pitsiou G. G., Trigonis I., et al. Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension. Respirology: 2011; 16 3 451 458
56. Devaraj A., Wells A. U., Meister M. G., Corte T. J., Hansell D. M. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology: 2008; 249 3 1042 1049
57. Tan R. T., Kuzo R., Goodman L. R., Siegel R., Haasler G. B., Presberg K. W. Medical College of Wisconsin Lung Transplant Group Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest: 1998; 113 5 1250 1256
58. Murray T. I., Boxt L. M., Katz J., Reagan K., Barst R. J. Estimation of pulmonary artery pressure in patients with primary pulmonary hypertension by quantitative analysis of magnetic resonance images. J Thorac Imaging: 1994; 9 3 198 204
59. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol: 1998; 31 1 202 208
60. Krüger S., Graf J., Kunz D., Stickel T., Hanrath P., Janssens U. brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol: 2002; 40 4 718 722
61. Leuchte H. H., Neurohr C., Baumgartner R., et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med: 2004; 170 4 360 365
62. Leuchte H. H., Baumgartner R. A., Nounou M. E., et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med: 2006; 173 7 744 750
63. Corte T. J., Wort S. J., Gatzoulis M. A., et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J: 2010; 36 4 819 825
64. Song J. W., Song J. K., Kim D. S. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med: 2009; 103 2 180 186
65. Verma G., Marras T., Chowdhury N., Singer L. Health-related quality of life and 6. min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J: 2011; 18 5 283 287
66. Lederer D. J., Caplan-Shaw C. E., O'Shea M. K., et al. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant: 2006; 6 2 398 403
67. Lederer D. J., Arcasoy S. M., Barr R. G., et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant: 2006; 6 10 2436 2442
68. Hamada K., Nagai S., Tanaka S., et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest: 2007; 131 3 650 656
69. Alam S., Palevsky H. I. Standard therapies for pulmonary arterial hypertension. Clin Chest Med: 2007; 28 1 91 115, viii
70. O'Callaghan D. S., Gaine S. P. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med: 2007; 28 1 169 185, ix
71. Galiè N., Torbicki A., Barst R., et al. Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J: 2004; 25 24 2243 2278
72. Galiè N., Hoeper M. M., Humbert M., et al. ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J: 2009; 30 20 2493 2537
73. Pitsiou G., Papakosta D., Bouros D. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration: 2011; 82 3 294 304
74. Olschewski H., Ghofrani H. A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med: 1999; 160 2 600 607
75. Ghofrani H. A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet: 2002; 360 9337 895 900
76. Collard H. R., Anstrom K. J., Schwarz M. I., Zisman D. A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest: 2007; 131 3 897 899
77. Han M. K., Bach D. S., Hagan P., et al. Sildenafil Preserves Exercise Capacity in IPF Patients with Right Ventricular Dysfunction. Chest: 2013;;(Jan): 24
78. Zisman D. A., Schwarz M., Anstrom K. J., Collard H. R., Flaherty K. R., Hunninghake G. W. Idiopathic Pulmonary Fibrosis Clinical Research Network A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med: 2010; 363 7 620 628
79. Corte T. J., Gatzoulis M. A., Parfitt L., Harries C., Wells A. U., Wort S. J. The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology: 2010; 15 8 1226 1232
80. Raghu G., King T. E. Jr, Behr J., et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J: 2010; 35 1 118 123
81. King T. E. Jr, Behr J., Brown K. K., et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2008; 177 1 75 81
82. King T. E. Jr, Brown K. K., Raghu G., et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2011; 184 1 92 99
83. Saggar R., Ross D., Lynch J. III, Faul J. L. Pulmonary arterial hypertension and lung transplantation. In: Lynch J. P. III, Ross D. J., eds. Lung and Heart-Lung Transplantation. New York, NY Taylor & Francis Group: 2006; 147 165
84. Whitson B. A., Nath D. S., Johnson A. C., et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg: 2006; 131 1 73 80
85. Thabut G., Vinatier I., Stern J. B., et al. Primary graft failure following lung transplantation: predictive factors of mortality. Chest: 2002; 121 6 1876 1882
86. Christie J. D., Kotloff R. M., Pochettino A., et al. Clinical risk factors for primary graft failure following lung transplantation. Chest: 2003; 124 4 1232 1241
87. Fang A., Studer S., Kawut S. M., et al. Lung Transplant Outcomes Group. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest: 2011; 139 4 782 787
88. Lynch J. P. III, Kazerooni E. A., Gay S. E. Pulmonary sarcoidosis. Clin Chest Med: 1997; 18 4 755 785
89. Lynch J. P. III, Ma Y. L., Koss M. N., White E. S. Pulmonary sarcoidosis. Semin Respir Crit Care Med: 2007; 28 1 53 74
90. Judson M. A. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med: 2007; 28 1 83 101
91. Costabel U., Hunninghake G. W. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J: 1999; 14 4 735 737
92. Shorr A. F., Helman D. L., Davies D. B., Nathan S. D. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest: 2004; 125 3 990 996
93. Mitchell D. N., Scadding J. G. Sarcoidosis. Am Rev Respir Dis: 1974; 110 6 774 802
94. Rizzato G., Pezzano A., Sala G., et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis: 1983; 64 2 121 128
95. Głuskowski J., Hawryłkiewicz I., Zych D., Wojtczak A., Zieliński J. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration: 1984; 46 1 26 32
96. Battesti J. P., Georges R., Basset F., Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax: 1978; 33 1 76 84
97. Handa T., Nagai S., Miki S., et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest: 2006; 129 5 1246 1252
98. Sulica R., Teirstein A. S., Kakarla S., Nemani N., Behnegar A., Padilla M. L. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest: 2005; 128 3 1483 1489
99. Milman N., Burton C. M., Iversen M., Videbaek R., Jensen C. V., Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant: 2008; 27 3 329 334
100. Arcasoy S. M., Christie J. D., Pochettino A., et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest: 2001; 120 3 873 880
101. Shorr A. F., Davies D. B., Nathan S. D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest: 2003; 124 3 922 928
102. Gluskowski J., Hawrylkiewicz I., Zych D., Zieliński J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J: 1990; 3 4 403 407
103. Shorr A. F., Helman D. L., Davies D. B., Nathan S. D. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J: 2005; 25 5 783 788
104. Baughman R. P. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther: 2007; 9 02 S8
105. Preston I. R., Klinger J. R., Landzberg M. J., Houtchens J., Nelson D., Hill N. S. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest: 2001; 120 3 866 872
106. Rosen Y., Moon S., Huang C. T., Gourin A., Lyons H. A. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med: 1977; 101 4 170 174
107. Takemura T., Matsui Y., Saiki S., Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol: 1992; 23 11 1216 1223
108. Fahy G. J., Marwick T., McCreery C. J., Quigley P. J., Maurer B. J. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest: 1996; 109 1 62 66
109. Deng J. C., Baughman R. P., Lynch J. P. III. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med: 2002; 23 6 513 527
110. Shlobin O. A., Nathan S. D. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J: 2012; 39 6 1520 1533
111. Emirgil C., Sobol B. J., Herbert W. H., Trout K. The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function. Chest: 1971; 60 4 371 378
112. Baughman R. P., Sparkman B. K., Lower E. E. Six-minute walk test and health status assessment in sarcoidosis. Chest: 2007; 132 1 207 213
113. Bourbonnais J. M., Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J: 2008; 32 2 296 302
114. Baughman R. P., Engel P. J., Taylor L., Lower E. E. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest: 2010; 138 5 1078 1085
115. Fisher K. A., Serlin D. M., Wilson K. C., Walter R. E., Berman J. S., Farber H. W. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest: 2006; 130 5 1481 1488
116. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir. Rev: 2009; 18 111 29 34
117. Baughman R. P., Judson M. A., Lower E. E., et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis: 2009; 26 2 110 120
118. Baughman R. P., Engel P. J., Meyer C. A., Barrett A. B., Lower E. E. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis: 2006; 23 2 108 116
119. Barnett C. F., Bonura E. J., Nathan S. D., et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest: 2009; 135 6 1455 1461
120. Foley R. J., Metersky M. L. Successful treatment of sarcoidosis- associated pulmonary hypertension with bosentan. Respiration: 2008; 75 2 211 214
121. Sharma S., Kashour T., Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J: 2005; 32 3 405 410
122. Judson M. A., Highland K. B., Kwon S., et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis: 2011; 28 2 139 145
123. Vassallo R., Ryu J. H., Colby T. V., Hartman T., Limper A. H. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med: 2000; 342 26 1969 1978
124. Vassallo R., Ryu J. H., Schroeder D. R., Decker P. A., Limper A. H. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med: 2002; 346 7 484 490
125. Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J: 2006; 27 6 1272 1285
126. Basset F., Corrin B., Spencer H., et al. Pulmonary histiocytosis X. Am Rev Respir Dis: 1978; 118 5 811 820
127. Friedman P. J., Liebow A. A., Sokoloff J. Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult. Medicine (Baltimore): 1981; 60 6 385 396
128. Chaowalit N., Pellikka P. A., Decker P. A., et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc: 2004; 79 10 1269 1275
129. Dauriat G., Mal H., Thabut G., et al. Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis. Transplantation: 2006; 81 5 746 750
130. Etienne B., Bertocchi M., Gamondes J. P., et al. Relapsing pulmonary Langerhans cell histiocytosis after lung transplantation. Am J Respir Crit Care Med: 1998; 157 1 288 291
131. Gabbay E., Dark J. H., Ashcroft T., et al. Recurrence of Langerhans' cell granulomatosis following lung transplantation. Thorax: 1998; 53 4 326 327
132. Harari S., Brenot F., Barberis M., Simmoneau G. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest: 1997; 111 4 1142 1144
133. Crausman R. S., Jennings C. A., Tuder R. M., Ackerson L. M., Irvin C. G., King T. E. Jr. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med: 1996; 153 1 426 435
134. Hamada K., Teramoto S., Narita N., Yamada E., Teramoto K., Kobzik L. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J: 2000; 15 2 421 423
135. Kiakouama L., Cottin V., Etienne-Mastroïanni B., Khouatra C., Humbert M., Cordier J. F. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. Eur Respir J: 2010; 36 1 202 204
136. Benyounes B., Crestani B., Couvelard A., Vissuzaine C., Aubier M. Steroid-responsive pulmonary hypertension in a patient with Langerhans' cell granulomatosis (histiocytosis X). Chest: 1996; 110 1 284 286
137. Ryu J. H., Moss J., Beck G. J., et al. NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med: 2006; 173 1 105 111
138. Johnson S. R. Lymphangioleiomyomatosis. Eur Respir J: 2006; 27 5 1056 1065
139. Johnson S. R., Cordier J. F., Lazor R., et al. Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J: 2010; 35 1 14 26
140. Harknett E. C., Chang W. Y., Byrnes S., et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM: 2011; 104 11 971 979
141. Schiavina M., Di Scioscio V., Contini P., et al. Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. Am J Respir Crit Care Med: 2007; 176 1 96 98
142. Adriaensen M. E., Schaefer-Prokop C. M., Duyndam D. A., Zonnenberg B. A., Prokop M. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol: 2011; 66 7 625 628
143. Muzykewicz D. A., Sharma A., Muse V., Numis A. L., Rajagopal J., Thiele E. A. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. J Med Genet: 2009; 46 7 465 468
144. Matsui K., Tatsuguchi A., Valencia J., et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol: 2000; 31 10 1242 1248
145. Avila N. A., Kelly J. A., Chu S. C., Dwyer A. J., Moss J. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology: 2000; 216 1 147 153
146. Bernstein S. M., Newell J. D. Jr, Adamczyk D., Mortenson R. L., King T. E. Jr, Lynch D. A. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med: 1995; 152 6, Pt 1 2138 2143
147. Taveira-Dasilva A. M., Rabel A., Gochuico B. R., Avila N. A., Moss J. Prevalence of uterine leiomyomas in lymphangioleiomyomatosis. Fertil Steril: 2011; 96 3 711 714, e1
148. Glasgow C. G., Taveira-DaSilva A., Pacheco-Rodriguez G., et al. Involvement of lymphatics in lymphangioleiomyomatosis. Lymphat Res Biol: 2009; 7 4 221 228
149. Taveira-DaSilva A. M., Moss J. Optimizing treatments for lymphangioleiomyomatosis. Expert Rev Respir Med: 2012; 6 3 267 276
150. Kitaichi M., Nishimura K., Itoh H., Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med: 1995; 151 2, Pt 1 527 533
151. Taylor J. R., Ryu J., Colby T. V., Raffin T. A. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med: 1990; 323 18 1254 1260
152. Johnson S. R., Tattersfield A. E. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med: 1999; 160 2 628 633
153. Taveira-DaSilva A. M., Stylianou M. P., Hedin C. J., Hathaway O., Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest: 2004; 126 6 1867 1874
154. Bissler J. J., McCormack F. X., Young L. R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med: 2008; 358 2 140 151
155. McCormack F. X., Inoue Y., Moss J., et al. National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med: 2011; 364 17 1595 1606
156. Taveira-DaSilva A. M., Hathaway O., Stylianou M., Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med: 2011; 154 12 797 805, W-292-W-293
157. Moua T., Olson E. J., Jean H. C., Ryu J. H. Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy. Am J Respir Crit Care Med: 2012; 186 4 389 390
158. Neurohr C., Hoffmann A. L., Huppmann P., et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis? Respir Res: 2011; 12 66
159. Boehler A., Speich R., Russi E. W., Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med: 1996; 335 17 1275 1280
160. Pechet T. T., Meyers B. F., Guthrie T. J., et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant: 2004; 23 3 301 308
161. Maurer J. R., Ryu J., Beck G., et al. National Heart, Lung, and Blood Institute LAM Registry Study Group. Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry. J Heart Lung Transplant: 2007; 26 12 1293 1299
162. Kpodonu J., Massad M. G., Chaer R. A., et al. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. J Heart Lung Transplant: 2005; 24 9 1247 1253
163. Taveira-DaSilva A. M., Hathaway O. M., Sachdev V., Shizukuda Y., Birdsall C. W., Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest: 2007; 132 5 1573 1578
164. Reynaud-Gaubert M., Mornex J. F., Mal H., et al. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation: 2008; 86 4 515 520
165. Harari S., Simonneau G., De Juli E., et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant: 1997; 16 4 460 463
166. Simonneau G., Robbins I. M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol: 2009; 54 (1, Suppl): S43 S54
167. Walter R. E., Wilk J. B., Larson M. G., et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest: 2008; 133 1 19 25
168. Cuttica M. J., Kalhan R., Shlobin O. A., et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med: 2010; 104 12 1877 1882
169. Thabut G., Dauriat G., Stern J. B., et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest: 2005; 127 5 1531 1536
170. Andersen K. H., Iversen M., Kjaergaard J., et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant: 2012; 31 4 373 380
171. Scharf S. M., Iqbal M., Keller C., Criner G., Lee S., Fessler H. E. National Emphysema Treatment Trial (NETT) Group Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med: 2002; 166 3 314 322
172. Stevens D., Sharma K., Szidon P., Rich S., McLaughlin V., Kesten S. Severe pulmonary hypertension associated with COPD. Ann Transplant: 2000; 5 3 8 12
173. Hugues T., Lemoigne F., Macone F., Cerboni P., Gibelin P. [Disproportionate pulmonary arterial hypertension and lung respiratory diseases: distinctive clinical, hemodynamic and prognosis of patients versus primary pulmonary arterial hypertension]. Ann Cardiol Angeiol (Paris): 2012; 61 1 1 7
174. Murray T. R., Chen L., Marshall B. E., Macarak E. J. Hypoxic contraction of cultured pulmonary vascular smooth muscle cells. Am J Respir Cell Mol Biol: 1990; 3 5 457 465
175. Peinado V. I., Santos S., Ramírez J., Roca J., Rodriguez-Roisin R., Barberà J. A. Response to hypoxia of pulmonary arteries in chronic obstructive pulmonary disease: an in vitro study. Eur Respir J: 2002; 20 2 332 338
176. Hales C. A. The site and mechanism of oxygen sensing for the pulmonary vessels. Chest: 1985; 88 (4, Suppl): 235S 240S
177. Meyrick B., Reid L. The effect of continued hypoxia on rat pulmonary arterial circulation. An ultrastructural study. Lab Invest: 1978; 38 2 188 200
178. Barberà J. A., Riverola A., Roca J., et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 1994; 149 2, Pt 1 423 429
179. Wright J. L., Petty T., Thurlbeck W. M. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung: 1992; 170 2 109 124
180. Matsuoka S., Washko G. R., Yamashiro T., et al. National Emphysema Treatment Trial Research Group. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med: 2010; 181 3 218 225
181. Butler J., Schrijen F., Henriquez A., Polu J. M., Albert R. K. Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease. Am Rev Respir Dis: 1988; 138 2 350 354
182. Schrijen F. V., Henriquez A., Carton D., Delorme N., Butler J. Pulmonary vascular resistance rises with lung volume on exercise in obstructed airflow disease. Clin Physiol: 1989; 9 2 143 150
183. Santos S., Peinado V. I., Ramírez J., et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J: 2002; 19 4 632 638
184. Su Y., Han W., Giraldo C., De Li Y., Block E. R. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol: 1998; 19 5 819 825
185. Yamato H., Sun J. P., Churg A., Wright J. L. Guinea pig pulmonary hypertension caused by cigarette smoke cannot be explained by capillary bed destruction. J Appl Physiol: 1997; 82 5 1644 1653
186. Schiess R., Senn O., Fischler M., et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest: 2010; 138 5 1086 1092
187. Seimetz M., Parajuli N., Pichl A., et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell: 2011; 147 2 293 305
188. Peinado V. I., Barberá J. A., Abate P., et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 1999; 159 5, Pt 1 1605 1611
189. Chaouat A., Savale L., Chouaid C., et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest: 2009; 136 3 678 687
190. Churg A., Marshall C. V., Sin D. D., et al. Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2012; 185 1 34 43
191. Wick M. J., Buesing E. J., Wehling C. A., et al. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2011; 183 3 330 340
192. Voelkel N. F., Gomez-Arroyo J., Mizuno S. COPD/emphysema: The vascular story. Pulm Circ: 2011; 1 3 320 326
193. Peinado V. I., Barbera J. A., Ramirez J., et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol: 1998; 274 6, Pt 1 L908 L913
194. Dinh-Xuan A. T., Higenbottam T. W., Clelland C. A., et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med: 1991; 324 22 1539 1547
195. Noureddine H., Gary-Bobo G., Alifano M., et al. Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease. Circ Res: 2011; 109 5 543 553
196. Oswald-Mammosser M., Apprill M., Bachez P., Ehrhart M., Weitzenblum E. Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type. Respiration: 1991; 58 5-6 304 310
197. Kiakouama L., Cottin V., Glerant J. C., Bayle J. Y., Mornex J. F., Cordier J. F. Conditions associated with severe carbon monoxide diffusion coefficient reduction. Respir Med: 2011; 105 8 1248 1256
198. Rizzato G. F., Rampulla C., Mandelli V., Benza G. C., Mantero O., Morpurgo M. Can pulmonary artery pressure be predicted without right heart catheterization in chronic obstructive lung disease? Acta Cardiol: 1975; 30 4 251 265
199. Sims M. W., Margolis D. J., Localio A. R., Panettieri R. A., Kawut S. M., Christie J. D. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest: 2009; 136 2 412 419
200. Bishop J. M., Cross K. W. Use of other physiological variables to predict pulmonary arterial pressure in patients with chronic respiratory disease. Multicentre study. Eur Heart J: 1981; 2 6 509 517
201. Ooi H., Cadogan E., Sweeney M., Howell K., O'Regan R. G., McLoughlin P. Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling. Am J Physiol Heart Circ Physiol: 2000; 278 2 H331 H338
202. Hurdman J., Condliffe R., Elliot C. A., et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J: 2012; 39 4 945 955
203. Burrows B., Kettel L. J., Niden A. H., Rabinowitz M., Diener C. F. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med: 1972; 286 17 912 918
204. Oswald-Mammosser M., Weitzenblum E., Quoix E., et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest: 1995; 107 5 1193 1198
205. Weitzenblum E., Hirth C., Ducolone A., Mirhom R., Rasaholinjanahary J., Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax: 1981; 36 10 752 758
206. Skwarski K., MacNee W., Wraith P. K., Sliwinski P., Zielinski J. Predictors of survival in patients with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Chest: 1991; 100 6 1522 1527
207. Report of the Medical Research Council Working Party Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet: 1981; 1 8222 681 686
208. Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med: 1980; 93 3 391 398
209. Keller R., Ragaz A., Borer P. Predictors for early mortality in patients with long-term oxygen home therapy. Respiration: 1985; 48 3 216 221
210. Finlay M., Middleton H. C., Peake M. D., Howard P. Cardiac output, pulmonary hypertension, hypoxaemia and survival in patients with chronic obstructive airways disease. Eur J Respir Dis: 1983; 64 4 252 263
211. Stone A. C., Machan J. T., Mazer J., Casserly B., Klinger J. R. Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung: 2011; 189 3 207 212
212. Orens J. B., Estenne M., Arcasoy S., et al. Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant: 2006; 25 7 745 755
213. Kessler R., Faller M., Fourgaut G., Mennecier B., Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 1999; 159 1 158 164
214. McGhan R., Radcliff T., Fish R., Sutherland E. R., Welsh C., Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest: 2007; 132 6 1748 1755
215. Wells J. M., Washko G. R., Han M. K., et al. COPDGene Investigators; ECLIPSE Study Investigators. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med: 2012; 367 10 913 921
216. Abraham A. S., Cole R. B., Green I. D., Hedworth-Whitty R. B., Clarke S. W., Bishop J. M. Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studies by serial observations during recovery. Circ Res: 1969; 24 1 51 60
217. Akcay M., Yeter E., Durmaz T., et al. Treatment of acute chronic obstructive pulmonary disease exacerbation improves right ventricle function. Eur J Echocardiogr: 2010; 11 6 530 536
218. Weitzenblum E., Schrijen F., Mohan-Kumar T., Colas des Francs V., Lockhart A. Variability of the pulmonary vascular response to acute hypoxia in chronic bronchitis. Chest: 1988; 94 4 772 778
219. Fletcher E. C., Levin D. C. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. Chest: 1984; 85 1 6 14
220. Raeside D. A., Brown A., Patel K. R., Welsh D., Peacock A. J. Ambulatory pulmonary artery pressure monitoring during sleep and exercise in normal individuals and patients with COPD. Thorax: 2002; 57 12 1050 1053
221. Catterall J. R., Douglas N. J., Calverley P. M., et al. Transient hypoxemia during sleep in chronic obstructive pulmonary disease is not a sleep apnea syndrome. Am Rev Respir Dis: 1983; 128 1 24 29
222. Sabit R., Bolton C. E., Fraser A. G., et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med: 2010; 104 8 1171 1178
223. Oliver R. M., Fleming J. S., Waller D. G. Right ventricular function at rest and during exercise in chronic obstructive pulmonary disease. Comparison of two radionuclide techniques. Chest: 1993; 103 1 74 80
224. Pynnaert C., Lamotte M., Naeije R. Aerobic exercise capacity in COPD patients with and without pulmonary hypertension. Respir Med: 2010; 104 1 121 126
225. Boerrigter B. G., Bogaard H. J., Trip P., et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest: 2012; 142 5 1166 1174
226. Fisher M. R., Criner G. J., Fishman A. P., et al. NETT Research Group. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J: 2007; 30 5 914 921
227. Oswald-Mammosser M., Oswald T., Nyankiye E., Dickele M. C., Grange D., Weitzenblum E. Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy. Eur J Respir Dis: 1987; 71 5 419 429
228. Tramarin R., Torbicki A., Marchandise B., Laaban J. P., Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. Working Group on Noninvasive Evaluation of Pulmonary Artery Pressure. European Office of the World Health Organization, Copenhagen. Eur Heart J: 1991; 12 2 103 111
229. Chi S. Y., Kim E. Y., Ban H. J., et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung: 2012; 190 3 271 276
230. Weitzenblum E., Sautegeau A., Ehrhart M., Mammosser M., Hirth C., Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis: 1984; 130 6 993 998
231. Kessler R., Faller M., Weitzenblum E., et al. "Natural historyo" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med: 2001; 164 2 219 224
232. Rizkallah J., Man S. F., Sin D. D. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest: 2009; 135 3 786 793
233. Rao B. S., Cohn K. E., Eldridge F. E., Hancock E. W. Left ventricular failure secondary to chronic pulmonary disease. Aspen Emphysema Conf: 1968; 11 129 134
234. Barr R. G., Bluemke D. A., Ahmed F. S., et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med: 2010; 362 3 217 227
235. Watz H., Waschki B., Meyer T., et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest: 2010; 138 1 32 38
236. Anderson W. J., Lipworth B. J. Relationships between impulse oscillometry, spirometry and dyspnoea in COPD. J R Coll Physicians Edinb: 2012; 42 2 111 115
237. Wiggins J., Strickland B., Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med: 1990; 84 5 365 369
238. Hiwatari N., Shimura S., Takishima T. Pulmonary emphysema followed by pulmonary fibrosis of undetermined cause. Respiration: 1993; 60 6 354 358
239. Doherty M. J., Pearson M. G., O'Grady E. A., Pellegrini V., Calverley P. M. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax: 1997; 52 11 998 1002
240. Aduen J. F., Zisman D. A., Mobin S. I., et al. Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. Mayo Clin Proc: 2007; 82 1 48 54
241. Mejía M., Carrillo G., Rojas-Serrano J., et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest: 2009; 136 1 10 15
242. Jankowich M. D., Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung: 2010; 188 5 365 373
243. Akagi T., Matsumoto T., Harada T., et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med: 2009; 103 8 1209 1215
244. Kurashima K., Takayanagi N., Tsuchiya N., et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology: 2010; 15 5 843 848
245. Todd N. W., Jeudy J., Lavania S., et al. Centrilobular emphysema combined with pulmonary fibrosis results in improved survival. Fibrogenesis Tissue Repair: 2011; 4 1 6
246. Cottin V., Nunes H., Brillet P. Y., et al. Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J: 2005; 26 4 586 593
247. Cottin V., Le Pavec J., Prévot G., et al. GERMo"Oo"P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J: 2010; 35 1 105 111
248. Morrell N. W., Sarybaev A. S., Alikhan A., Mirrakhimov M. M., Aldashev A. A. ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders. Lancet: 1999; 353 9155 814
249. van Suylen R. J., Wouters E. F., Pennings H. J., et al. The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 1999; 159 6 1791 1795
250. Eddahibi S., Chaouat A., Morrell N., et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation: 2003; 108 15 1839 1844
251. Shaw J. G., Dent A. G., Passmore L. H., et al. Genetic influences on right ventricular systolic pressure (RVSP) in chronic obstructive pulmonary disease (COPD). BMC Pulm Med: 2012; 12 25
252. Castaldi P. J., Cho M. H., Cohn M., et al. The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum Mol Genet: 2010; 19 3 526 534
253. Eddahibi S., Chaouat A., Tu L., et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc: 2006; 3 6 475 476
254. Yildiz P., Oflaz H., Cine N., Erginel-Unaltuna N., Erzengin F., Yilmaz V. Gene polymorphisms of endothelial nitric oxide synthase enzyme associated with pulmonary hypertension in patients with COPD. Respir Med: 2003; 97 12 1282 1288
255. Kanazawa H., Tateishi Y., Yoshikawa J. Acute effects of nifedipine administration in pulmonary haemodynamics and oxygen delivery during exercise in patients with chronic obstructive pulmonary disease: implication of the angiotensin-converting enzyme gene polymorphisms. Clin Physiol Funct Imaging: 2004; 24 4 224 228
256. Kanazawa H., Hirata K., Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax: 2003; 58 7 629 631
257. Kanazawa H., Okamoto T., Hirata K., Yoshikawa J. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med: 2000; 162 4, Pt 1 1235 1238
258. de Torres J. P., Cote C. G., López M. V., et al. Sex differences in mortality in patients with COPD. Eur Respir J: 2009; 33 3 528 535
259. Ekström M. P., Jogréus C., Ström K. E. Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease. PLoS ONE: 2012; 7 4 e35806
260. Shimizu M., Imanishi J., Takano T., Miwa Y. Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension. Intern Med: 2011; 50 20 2341 2346
261. Dernaika T. A., Beavin M., Kinasewitz G. T. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration: 2010; 79 5 377 382
262. Barberà J. A., Roger N., Roca J., Rovira I., Higenbottam T. W., Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet: 1996; 347 8999 436 440
263. Vonbank K., Ziesche R., Higenbottam T. W., et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax: 2003; 58 4 289 293
264. Blanco I., Gimeno E., Munoz P. A., et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med: 2010; 181 3 270 278
265. Holverda S., Rietema H., Bogaard H. J., et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther: 2008; 21 3 558 564
266. Lederer D. J., Bartels M. N., Schluger N. W., et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD: 2012; 9 3 268 275
267. Namendys-Silva S. A., Hernández-Garay M. Should we administer sildenafil to patients with obstructive pulmonary disease and pulmonary hypertension? No. Am J Respir Crit Care Med: 2010; 182 9 1206, author reply 1206-1207
268. Kim H. S., Park J. H., Park S. J., Park J. K., Lee H. B. Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. Korean J Intern Med: 2007; 22 1 37 39
269. Park J. S., Lim H. J., Cho Y. J., Lee J. H., Yoon H. I., Lee C. T. Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study. COPD: 2012; 9 5 499 504
270. Stolz D., Rasch H., Linka A., et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J: 2008; 32 3 619 628
271. Mercurio V., Carlomagno G., Fazio S. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. Heart Lung: 2012; 41 5 512 517
272. Reed R. M., Iacono A., DeFilippis A., et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD: 2011; 8 2 96 102
273. Wright J. L., Zhou S., Preobrazhenska O., et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med: 2011; 183 1 50 58
274. Wu D., Lee D., Sung Y. K. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res: 2011; 12 45
275. Zakynthinos E., Daniil Z., Papanikolaou J., Makris D. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Curr Drug Targets: 2011; 12 4 501 513
276. Barberà J. A., Peinado V. I. Vascular progenitor cells in chronic obstructive pulmonary disease. Proc Am Thorac Soc: 2011; 8 6 528 534
277. Dumas de La Roque E., Savineau J. P., Metivier A. C., et al. Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study. Ann Endocrinol (Paris): 2012; 73 1 20 25